热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 抗体 配对抗体

所有图片（1/1）

CCL17 Recombinant Rabbit mAb (SDT-1847-112)

C-C motif chemokine 17,CC chemokine TARC,Small-inducible cytokine A17,Thymus and activation-regulated chemokine,SCYA17,TARC

价格 询价 请咨询客服
货号 S0B3673
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 宿主来源

    Rabbit

  • 抗原名称

    CCL17

  • 分子别名

    C-C motif chemokine 17; CC chemokine TARC; Small-inducible cytokine A17; Thymus and activation-regulated chemokine; SCYA17; TARC

  • 免疫原

    Recombinant Protein

  • Accession

    Q92583

  • 克隆号

    SDT-1847-112

  • 抗体类型

    Recombinant mAb

  • 抗体同种型

    IgG

  • 反应种属 ?

    Hu

  • 交叉反应

    No cross-reactivity against CCL2, CCL3, CCL4, CXCL1

  • 纯化方式

    Protein A

  • 浓度

    2 mg/ml

  • 标记

    Unconjugated

  • 性状

    Liquid

  • 缓冲体系

    PBS pH7.4, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt, 2 to 8 °C as supplied

  • 应用

    Sandwich ELISA

背景介绍

  • CCL17, also known as Thymus and Activation-Regulated Chemokine (TARC), is a protein that belongs to the C-C chemokine family. It is primarily produced by dendritic cells, endothelial cells, keratinocytes, and fibroblasts, and is highly expressed in the thymus. CCL17 plays a crucial role in immune regulation by recruiting lymphocytes and modulating immune function. It acts as a ligand for the C-C chemokine receptor type 4 (CCR4), which is highly expressed on helper T cells. This chemokine is involved in various biological processes, including T-cell development, trafficking, and activation of mature T cells. Additionally, CCL17 has been implicated in several diseases, such as chronic kidney disease, where it may promote renal fibrosis by inducing epithelial-mesenchymal transition. In the context of cancer, CCL17 can influence the tumor microenvironment by recruiting regulatory T cells and affecting tumor progression.

  • 配对推荐

评论(0)